Associated tags: Ulcerative colitis, Cystic fibrosis, FW, First wave, Niclosamide, Nutrient, Digestion, CP, Exocrine pancreatic insufficiency, Patient, Fats, BOCA, Pharmaceutical industry, EPI, Clinical trial
Locations: NEW YORK CITY, CALIFORNIA, NY, WASHINGTON, RALEIGH, BRAZIL, MASSACHUSETTS, BOSTON, NEWPORT BEACH, BOCA RATON, FL, US, PUERTO RICO, NEW JERSEY, EPI, CF, FLORIDA
Gastrointestinal disease,
Fear,
First wave,
Safety,
Research,
Coeliac disease,
GI,
Child,
BOCA,
Quality of life,
Dentistry The digital display will also be shown at night as part of the international “ Shine a Light on Celiac Disease ” initiative to illuminate famous landmarks in green.
Key Points:
- The digital display will also be shown at night as part of the international “ Shine a Light on Celiac Disease ” initiative to illuminate famous landmarks in green.
- First Wave BioPharma will also host a photo event at the Nasdaq Market Site featuring celiac disease advocates and experts who will share their lived experiences with celiac disease.
- “Celiac disease is a topical issue at the forefront of many people’s lives,” said James Sapirstein, Chairman and Chief Executive Officer of First Wave BioPharma.
- I’m grateful to First Wave BioPharma and Nasdaq for helping us shine a light on celiac disease this May.”
“As a parent of a child living with celiac disease, I understand firsthand the daily challenges and fears associated with this condition,” said Jon Bari, Co-founder of Celiac Journey.
Retrieved on:
Wednesday, April 24, 2024
First wave,
CED,
Research,
Coeliac disease,
ULN,
Serology,
Patient,
Diet,
BOCA,
Manuscript,
Pharmaceutical industry Latiglutenase, an oral biotherapeutic composed of two gluten-specific recombinant proteases, is a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).
Key Points:
- Latiglutenase, an oral biotherapeutic composed of two gluten-specific recombinant proteases, is a potentially first-in-class, targeted, oral biotherapeutic for celiac disease (CeD).
- The featured paper is entitled “Dynamics of Serologic Change to Gluten in Celiac Disease Patients” (doi.org/10.3390/nu15245083).
- “Our focus on developing latiglutenase is bolstered by this groundbreaking CeD research, just one component of the scientific, clinical, and regulatory expertise in gastroenterological drug development that Jack Syage and his team, formerly from ImmunogenX, bring to First Wave,” stated James Sapirstein, Chairman and CEO of First Wave.
- “The evidence produced from this rich deposit of clinical data advances not only the development of latiglutenase but also benefits the whole field of celiac disease research in order to bring needed relief to the millions who suffer from this disease.”
Retrieved on:
Wednesday, April 17, 2024
BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Planet MicroCap Showcase, which will be held April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas.
Key Points:
- BOCA RATON, Fla., April 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the Planet MicroCap Showcase, which will be held April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas.
- Details of the event are as follows:
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will participate in the Longwood Healthcare Leaders Conference, which will be held April 29 - May 1, 2024 at The Ritz-Carlton in Key Biscayne, Florida.
Key Points:
- BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will participate in the Longwood Healthcare Leaders Conference, which will be held April 29 - May 1, 2024 at The Ritz-Carlton in Key Biscayne, Florida.
- Details of the event are as follows:
Inflammation,
Health,
Conference,
Database,
Patient,
Serology,
Research,
Lymphocyte,
Gastrointestinal disease,
Doctor of Philosophy,
CED,
First wave,
Abstract,
Gastroenterology,
DDW,
Coeliac disease,
IEL BOCA RATON, Fla., March 18, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024, in Washington, D.C.
Key Points:
- “The abstracts accepted for presentation at DDW 2024 showcase significant advancements in the field of gastroenterology, particularly in the precision diagnosis and management of celiac disease through the innovative VCIEL scale that our team has developed,” stated James Sapirstein, Chairman and CEO of First Wave BioPharma.
- Details on the presentations are as follows:
Jack Syage, PhD.
- President & Chief Operating Officer, First Wave BioPharma
Jack Syage, PhD.
- President & Chief Operating Officer, First Wave BioPharma
Conference,
Webcast,
Patient,
Common,
Fats,
GI,
Acquisition,
First wave,
NIH,
Gastrointestinal disease,
Series,
Marketing,
Gastroparesis,
FDA,
Cystic fibrosis,
Food,
Digestion,
Pharmaceutical industry BOCA RATON, Fla., March 14, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced it has acquired ImmunogenX in an all-stock transaction with the combined company focused on advancing a GI pipeline comprised of multiple, late-stage clinical assets, including latiglutenase, a potentially first-in-class, near Phase 3-ready, targeted, oral biotherapeutic for celiac disease. James Sapirstein will continue to serve as Chairman and Chief Executive Officer of First Wave BioPharma with Jack Syage, Ph.D., previously the Chief Executive Officer and Co-Founder of ImmunogenX, assuming the role of President and Chief Operating Officer of First Wave BioPharma. Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.
Key Points:
- Dr. Syage and Dr. Chaitan Khosla will also join the board of directors of First Wave BioPharma.
- First Wave BioPharma intends to license the commercial rights to latiglutenase in the United States and Canada to a strategic global pharmaceutical company which will commercialize latiglutenase following receipt of marketing approval.
- First Wave BioPharma will also seek to secure financing commitments from a syndicate of institutional healthcare investors to fund the ongoing development of latiglutenase.
- First Wave BioPharma will host a conference call and live audio webcast today, March 14, 2024, at 8:30 a.m.
BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced James Sapirstein, Chairman, President and CEO, will participate in a “fireside chat” with Jonathan Aschoff, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, during the 36th Annual Roth Conference being held March 17-19, 2024, at the Ritz Carlton, Laguna Niguel in Dana Point, California.
Key Points:
- BOCA RATON, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced James Sapirstein, Chairman, President and CEO, will participate in a “fireside chat” with Jonathan Aschoff, Ph.D., Managing Director and Senior Research Analyst at Roth Capital Partners, during the 36th Annual Roth Conference being held March 17-19, 2024, at the Ritz Carlton, Laguna Niguel in Dana Point, California.
- Details of the presentation are as follows:
In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 525,625 shares of common stock.
Key Points:
- In addition, in a concurrent private placement, the Company will issue to the investors warrants to purchase up to 525,625 shares of common stock.
- Roth Capital Partners is acting as the exclusive placement agent for the offering.
- The gross proceeds to the Company from this offering are expected to be approximately $4.0 million, before deducting the placement agent's fees and other offering expenses payable by the Company.
- The Company intends to use the net proceeds from this offering for working capital and general corporate purposes.
Retrieved on:
Tuesday, February 13, 2024
BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the BIO CEO & Investor Conference, which is planned for February 26-27, 2024, at the Marriott Marquis in New York City.
Key Points:
- BOCA RATON, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, will present at the BIO CEO & Investor Conference, which is planned for February 26-27, 2024, at the Marriott Marquis in New York City.
- Details of the event are as follows:
Retrieved on:
Tuesday, January 23, 2024
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the DealFlow MicroCap Conference, which will be held January 30 – February 1, 2024 at the Caesars Atlantic City Hotel & Casino, in Atlantic City, New Jersey.
Key Points:
- BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it will present at the DealFlow MicroCap Conference, which will be held January 30 – February 1, 2024 at the Caesars Atlantic City Hotel & Casino, in Atlantic City, New Jersey.
- Details of the event are as follows:
